A combination of two existing drugs is highly effective against SARS-CoV-2 in cell cultures, researchers in Norway and Estonia have found.
In a separate experiment, the researchers used the same cell cultures to show that convalescent blood plasma may be ineffective if the patient donated it 2 months after receiving a diagnosis of COVID-19. This is the respiratory disease that SARS-CoV-2 causes.
On June 16, 2020, scientists at the University of Oxford in the United Kingdom announced the first drug proven to reduce mortality in people with severe COVID-19.
The breakthrough, which the team will report in the journal Nature, means that doctors can immediately start treating hospitalized patients with dexamethasone. This is a cheap, readily available steroid that has been in widespread use for decades.
Drugs with a proven safety record, such as dexamethasone, have a clear advantage over novel treatments and vaccines; after a relatively swift clinical trial, national drug regulators can immediately approve their use.
Research by scientists in Norway and Estonia has now identified two more drugs that regulators could potentially fast-track in this way.
The drugs are antivirals that already have approval to treat other infections. Like dexamethasone, researchers would need to test their efficacy against SARS-CoV-2 in people with the virus.
In the new study, a group of scientists from the Norwegian University of Science and Technology in Trondheim collaborated with scientists at the University of Tartu in Estonia.
They first screened 12 human and animal cell lines to determine which was the most susceptible to the virus.
They identified one cell line called Vero-E6, which they extracted from African green monkeys, then they exposed cultures of these cells to SARS-CoV-2 plus varying concentrations of 136 antiviral drugs.
The drugs were from a database of broad-spectrum antiviral agents (BSAAs), which the same research team set up earlier in 2020. BSAAs are drugs that have passed a clinical safety trial and that work against two or more families of viruses.
After 72 hours, the researchers counted how many cells were still alive in each culture dish. This allowed them to narrow down the field to six drugs that were the most effective at rescuing cells from SARS-CoV-2.
The six antivirals that were active against the virus were:
Next, the scientists repeated the process using pairs of the drugs in combination.
Antivirals, such as those that treat HIV, often work synergistically that is, they are more powerful together than individually. Also, viruses are less likely to develop resistance to a combination of drugs.
Nelfinavir, an anti-HIV drug, and amodiaquine, an antimalarial drug, exhibited the strongest synergy of all the possible combinations.
Interestingly, one of these drugs works by shielding the host cells, while the other targets the virus itself. This is a combined strategy that the researchers say has worked well against other viral infections.
The team checked that this drug combination was effective against each of seven available strains of SARS-CoV-2.
The researchers have now published their results in the journal Viruses.
This orally available drug combination nelfinavir-amodiaquine inhibits the virus infection in cell cultures, says senior study author Denis Kainov, an associate professor in the Norwegian University of Science and Technologys Department of Clinical and Molecular Medicine. It should be tested further in preclinical studies and clinical trials now.
In a second set of experiments using the same monkey cell line, the researchers collaborated with doctors at St. Olavs Hospital in Trondheim, Norway, to test the efficacy of convalescent blood plasma.
For more than 100 years, doctors have used blood plasma, or serum, from people who have recovered from a particular infection to treat other people with the same infection.
Hospitals around the world are already using convalescent serum to treat COVID-19. However, although the treatment appears to be safe and large trials are underway, scientists have yet to prove its efficacy.
Concerns have emerged that the blood of some convalescent patients contains few, if any, antibodies that can neutralize the virus.
Regular antibody tests detect the presence of antibodies to the virus in plasma, but not all antibodies are able to kill or neutralize the virus.
So, to investigate further, the scientists used their monkey cells to develop a neutralizing antibody test for the virus.
When they exposed the cells to SARS-CoV-2 in the presence of plasma samples from people who have recovered, they discovered that the more recently the donor had recovered from COVID-19, the greater the neutralizing capacity of the serum.
By 2 months after diagnosis, serum did not contain enough antibodies to neutralize the virus.
This means if you collect blood from patients who have recovered from COVID-19 after 2 months from diagnosis of the disease and transfuse their plasma/serum to severely sick patients, it may not help, says study co-author Svein Arne Nordb, an associate professor in the Norwegian University of Science and Technologys Department of Clinical and Molecular Medicine.
The conclusion so far is that clinicians need to collect plasma for treatment purposes as soon as patients recover from COVID-19, says Nordb.
If someone had exposure to the virus a second time, however, their immune systems memory cells would likely start producing neutralizing antibodies again.
An important caveat of the new findings is that the cells the researchers used in the experiments were from monkeys, not humans.
Also, what happens in a dish of cells may not reflect what happens in a whole organism.
The researchers hope to conduct further research in animals, followed by a clinical trial in humans.
In the meantime, they have created a regularly updated website dedicated to available and emerging treatment options for SARS-CoV-2.
The researchers database of BSAAs and their research status with regard to particular viruses is also publicly available. They believe that it may prove a valuable resource in the event of future viral outbreaks.
Our bigger ambition is to assemble a toolbox of BSAAs for the treatment of emerging and re-emerging viral infections. This toolbox can be offered to the [World Health Organization] as a means for the fast identification of safe and effective antiviral options.
Study co-author Aleksandr Ianevski et al.
For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here.
Read more:
Duo of antiviral drugs strongly inhibits SARS-CoV-2 in the lab - Medical News Today
- Podcast 9 Athens part 3 and news - November 8th, 2009 [November 8th, 2009]
- Podcast 10 Athens part 4 - November 8th, 2009 [November 8th, 2009]
- Podcast 11 Athens Part 5 - November 8th, 2009 [November 8th, 2009]
- Episode 12 Cardiac Nuclear Medicine in the UK - November 8th, 2009 [November 8th, 2009]
- Podcast 13 Choline PET and prostate cancer - November 8th, 2009 [November 8th, 2009]
- Episode14 ED function and Dysponea - November 8th, 2009 [November 8th, 2009]
- ep 15 Collimator Choice and Reconstruction algorithm - November 8th, 2009 [November 8th, 2009]
- Episode 16 Dr Strauss on vulnerable plaque - November 8th, 2009 [November 8th, 2009]
- Episode17 Chemical Stress - November 8th, 2009 [November 8th, 2009]
- Episode 18 Myocardial Perfusion Imaging and Diabetes - November 8th, 2009 [November 8th, 2009]
- Episode 19 The INSPIRE trial - November 8th, 2009 [November 8th, 2009]
- 20 Dual isotope with a difference - November 8th, 2009 [November 8th, 2009]
- Episode 21 The real effect of stress - November 8th, 2009 [November 8th, 2009]
- Episode 22 D-SPECT - November 8th, 2009 [November 8th, 2009]
- Episode 23 VQ Reprise - November 8th, 2009 [November 8th, 2009]
- Episode 24 Hepatobiliary Nuclear Medicine - November 8th, 2009 [November 8th, 2009]
- Episode 25 Sleep Apnea - November 8th, 2009 [November 8th, 2009]
- Episode 26 Imaging Post Traumatic Stress Disorder - November 8th, 2009 [November 8th, 2009]
- Episode 27 Cardiac Stem Cells - November 8th, 2009 [November 8th, 2009]
- Episode 28 Molly Supply - November 8th, 2009 [November 8th, 2009]
- Episode 29 Melanoma therapy interview with Dr Ekaterina Dadachova - November 8th, 2009 [November 8th, 2009]
- Episode 30 Viral Therapy - November 8th, 2009 [November 8th, 2009]
- Episode 31 breast radiotherapy using radioisotopes - November 8th, 2009 [November 8th, 2009]
- Episode 32 news from snm - November 8th, 2009 [November 8th, 2009]
- Episode 33 EBV Imaging and Therapy - November 8th, 2009 [November 8th, 2009]
- Episode 34 Dr Lele SNM India 2009 - December 14th, 2009 [December 14th, 2009]
- Episode 35 Dr Andrew Scott from the Ludwig institute - January 10th, 2010 [January 10th, 2010]
- Episode 36 CardiArc - February 25th, 2010 [February 25th, 2010]
- Episode 37 Dr Modder Radiosynoviorthesis (Radiation Synovectomy) - March 31st, 2010 [March 31st, 2010]
- Episode 38 Indian Nuclear Medicine With Dr Malhotra and Dr Krishna - May 28th, 2010 [May 28th, 2010]
- Episode 39 Prof Ora Israel The Utility of Hybrid Imaging - July 13th, 2010 [July 13th, 2010]
- Episode 40 New V/Q SPECT developments - October 11th, 2010 [October 11th, 2010]
- Episode 41 scintimun - February 14th, 2011 [February 14th, 2011]
- Episode 42 Radio-Isotope Supply into the future - March 6th, 2011 [March 6th, 2011]
- Podcast 4: DNA therapy - April 24th, 2011 [April 24th, 2011]
- Sorry about the delay a new podcast will be out soon! - April 24th, 2011 [April 24th, 2011]
- Podcast 5 Flash 3D - April 24th, 2011 [April 24th, 2011]
- Podcast 6 Affibody - April 24th, 2011 [April 24th, 2011]
- Podcast 7 EANM 2006 Athens Part 1 - April 24th, 2011 [April 24th, 2011]
- Podcast 8 Athens Part 2 - April 24th, 2011 [April 24th, 2011]
- Episode 43 Rapidscan Part 1, 720P high quality video version - May 1st, 2011 [May 1st, 2011]
- Episode 43 Rapidscan Part 1, Ipod quality video - May 1st, 2011 [May 1st, 2011]
- Episode 43 Rapidscan Part 1, Audio version - May 1st, 2011 [May 1st, 2011]
- Episode 45 Mummies with cardiovascular disease video - May 21st, 2011 [May 21st, 2011]
- Episode 45 Mummies with cardiovascular disease audio edition - May 21st, 2011 [May 21st, 2011]
- Episode 46 Dr Gordon DePuey Choosing Reconstruction clinical perspective - August 7th, 2011 [August 7th, 2011]
- Episode 46 Dr Gordon DePuey Choosing Reconstruction clinical perspective audio version - August 7th, 2011 [August 7th, 2011]
- Episode 47 Cardiac Image Fusion With Dr Kaufmann - September 18th, 2011 [September 18th, 2011]
- Episode 47 Cardiac Fusion with Dr Kaufmann video version - September 18th, 2011 [September 18th, 2011]
- Dear Steve, I am and many more like me are your one more thing. - October 9th, 2011 [October 9th, 2011]
- EPISODE 48 PET MRI camera from Siemens with Dr Georgi audio - October 23rd, 2011 [October 23rd, 2011]
- EPISODE 48 PET MRI camera from Siemens Dr Georgi video - October 23rd, 2011 [October 23rd, 2011]
- Silicon Biosystems to Present Single-Circulating Tumor Cell Molecular Characterization at the Fourth World CTC Summit - April 25th, 2012 [April 25th, 2012]
- Leukaemia cells have a remembrance of things past - April 25th, 2012 [April 25th, 2012]
- Technologist Education Requirements Can Help Cut Repeat Scans - April 25th, 2012 [April 25th, 2012]
- HKU Collaborative Research Discovers A Novel Molecular Mechanism Of A New Anti-HIV-1 Drug Candidate - April 25th, 2012 [April 25th, 2012]
- Focal Segmental Glomerulosclerosis and the Nephrotic Syndrome - Part 1 Clinical - Video - May 4th, 2012 [May 4th, 2012]
- Electro-Medicine : Biological Physics - The Molecular Basis of Alzheimers Disease - Video - May 4th, 2012 [May 4th, 2012]
- osdd heterocyclic compounds and molecular medicines - Video - May 4th, 2012 [May 4th, 2012]
- Molecule to Medicine: The Biomarker Frontier - Video - May 4th, 2012 [May 4th, 2012]
- Fulfilling the Promise of Molecular Medicine in a Developmental Brain Disorder - Video - May 4th, 2012 [May 4th, 2012]
- Focus on Stefanie Dimmeler - Video - May 4th, 2012 [May 4th, 2012]
- Dundee - May 4th, 2012 [May 4th, 2012]
- Nanotechnology In Medicine: Huge Potential, But What Are The Risks? - May 5th, 2012 [May 5th, 2012]
- Cutting Edge Technology Coming To DMH - May 5th, 2012 [May 5th, 2012]
- This Week in Experimental and Molecular Pathology - May 5th, 2012 [May 5th, 2012]
- Researchers' discovery offers hope for cancer, heart disease miracle drugs - May 7th, 2012 [May 7th, 2012]
- Penn State student Zachary Hostetler from Garnet Valley is being honored as a student marshal - May 7th, 2012 [May 7th, 2012]
- NCKU Student Wins Prestigious Award for Anti-Cancer Research - May 10th, 2012 [May 10th, 2012]
- In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers ... - May 10th, 2012 [May 10th, 2012]
- Pitt team uses genomics to identify a molecular-based treatment for a viral skin cancer - May 10th, 2012 [May 10th, 2012]
- Genomics used to identify a molecular-based treatment for a viral skin cancer - May 10th, 2012 [May 10th, 2012]
- 2 molecular biologists get $500K medical prize - May 13th, 2012 [May 13th, 2012]
- 2 molecular biologists share $500K medical prize - May 13th, 2012 [May 13th, 2012]
- Lab21 Unveils New Molecular Analysis Services at Greenville Site - May 13th, 2012 [May 13th, 2012]
- 2 molecular biologists from NYC to share $500K medical prize for pioneering research on cells - May 13th, 2012 [May 13th, 2012]
- Two Molecular Biologists Get $500K Medical Prize - May 13th, 2012 [May 13th, 2012]
- Pair of molecular biologists receive Albany Medical Center Prize - May 13th, 2012 [May 13th, 2012]
- CNIO scientists successfully test the first gene therapy against aging-associated decline - May 16th, 2012 [May 16th, 2012]
- Cancer Institute of New Jersey Aims to Advance Personalized Cancer Treatments Through 'Precision Medicine' - May 16th, 2012 [May 16th, 2012]